CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO 2) Therapy, which delivers high levels of dissolved oxygen directly to the ...

CHELMSFORD, Mass., October 31, 2022--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated ...

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL ® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today it has received CE Mark ...

Asahi Kasei company Zoll has announced the enrolment of the first patient in a study of SuperSaturated Oxygen (SSO₂) Therapy for heart failure. This SuperSaturated Oxygen Comprehensive Observational ...

IRVINE, Calif.--(BUSINESS WIRE)--TherOx, a ZOLL ® Medical company, announces key data presentations and company-sponsored events for SuperSaturated Oxygen (SSO 2) Therapy at the upcoming Transcatheter ...

The Category III CPT code for SSO 2 Therapy was supported by the leadership of the Society for Cardiac Angiography and Interventions (SCAI) and the American College of Cardiology (ACC). The decision ...

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination ...

TherOx Inc., an Irvine-based medical device maker in business for more than 20 years and with more than $150 million invested in it over its history, has been acquired, two months after the company ...

Zoll Medical Corp., of Chelmsford, Mass., received CE mark approval to market its second-generation Supersaturated Oxygen (SSO 2) Therapy in Europe and other countries that accept CE mark. The therapy ...

Zoll Medical Corp., of Chelmsford, Mass., received CE mark approval to market its second-generation Supersaturated Oxygen (SSO 2) Therapy in Europe and other countries that accept CE mark. The therapy ...